Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Question For Noteable
View:
Post by pelaboost on May 13, 2024 3:26pm

Question For Noteable

ADCs

You say pelareorep is compatible with ADCs. I am not disagreeing. Please point me in the right direction. I thought it might have been one of the Ovarian trials, but they did not seem to include ADCs.


Thank you
Comment by Noteable on May 13, 2024 4:20pm
https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=36037484
Comment by Noteable on May 13, 2024 4:21pm
Ovarian cancer is also highly heterogenetic. https://pubmed.ncbi.nlm.nih.gov/29020678/
Comment by pelaboost on May 13, 2024 4:54pm
Got it. Thank you. Orphan status granted for Ovarian by FDA March 2, 2015 and EMA later in that same month. Cheers
Comment by pelaboost on May 14, 2024 11:02am
Heterogeneity and treatment landscape of ovarian carcinoma. A worthwhile read.
Comment by Noteable on May 13, 2024 7:15pm
Should read :   heterogeneic
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities